23andMe Discover23

23andMe launched the Discover23 platform, which evaluates associations of over 172 million genetic variants across 4.7 billion phenotypic data points from genome-wide association studies conducted on over 1,000 disease and condition cohorts. Biopharma customers will have access to summarized results of analyses conducted using deidentified data to help identify novel disease biology, discover potential new drug targets, and add genetic evidence to diverse research programs.